Literature DB >> 23801349

Unilateral phrenic nerve palsy: a rare manifestation of vincristine neurotoxicity.

Dhulika Dhingra1, Gulshan Rai Sethi, Mukta Mantan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23801349     DOI： 10.1007/s12098-013-1116-6

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  5 in total

1.  Phrenic nerve paralysis due to vincristine.

Authors:  Paul Gilliland; Mark Holguin
Journal:  Leuk Lymphoma       Date:  2007-12

2.  Vincristine induced cranial polyneuropathy.

Authors:  Ali Bay; Cahide Yilmaz; Nebi Yilmaz; Ahmet Faik Oner
Journal:  Indian J Pediatr       Date:  2006-06       Impact factor: 1.967

Review 3.  Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.

Authors:  J D Chan
Journal:  Pharmacotherapy       Date:  1998 Nov-Dec       Impact factor: 4.705

Review 4.  Nutritional neuropathies.

Authors:  Neeraj Kumar
Journal:  Neurol Clin       Date:  2007-02       Impact factor: 3.806

Review 5.  Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].

Authors:  I Magrath; V Shanta; S Advani; M Adde; L S Arya; S Banavali; M Bhargava; K Bhatia; M Gutiérrez; D Liewehr; S Pai; T G Sagar; D Venzon; V Raina
Journal:  Eur J Cancer       Date:  2005-01-05       Impact factor: 9.162
  5 in total
  2 in total

1.  Unilateral phrenic nerve palsy: a rare manifestation of vincristine neurotoxicity: authors' reply.

Authors:  Dhulika Dhingra; Gulshan Rai Sethi; Mukta Mantan
Journal:  Indian J Pediatr       Date:  2014-03-22       Impact factor: 1.967

2.  Unilateral phrenic nerve plasy: a rare manifestation of vincristine neurotoxicity: correspondence.

Authors:  Kunihiko Moriya; Yosuke Kakisaka; Masaei Onuma; Yoji Sasahara; Shigeo Kure
Journal:  Indian J Pediatr       Date:  2014-03-22       Impact factor: 1.967
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.